NCT05169619Completed
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
Epi-Asthma: Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
Source: ClinicalTrials.gov · Last updated 6 Mar 2025
Brief summary (registry, in English)
This study aims to determine the prevalence of Asthma, Difficult-to-Treat and Severe Asthma in Portugal, and characterize patients to better understand their disease characteristics, treatment profile and health care resource use to improve clinical management of the disease.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 842 (actual)
- First submitted
- 15 Nov 2021
- Start date
- 30 Apr 2021
- Primary completion date
- 6 Mar 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT05169619
What you commit to
- Study type: Observational
- Participants enrolled: 842
- From 30 Apr 2021 to the primary completion date, 6 Mar 2024
- 31 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants that have a physical condition that could interfere with the study assessments or prevent the participant from adequately participating in the study (e.g. mobility problems, not able to perform spirometry,…)
Who the study is looking for
- Adults =\>18 years old registered in Portuguese National Health service patients' database of primary care units.
- Give voluntary signed informed consent,
- Ability to understand ans answer questionnaires.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (31)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.